Wednesday, December 8, 2010

FDA Panel Not Contra Contrave

In contrast to previous recent negative recommendations on obesity drugs (Qnexa, lorcaserin, and sibutramine), yesterday, an Advisory Panel to the FDA voted 13/7 in favor of Orexigen Therapeutic’s new anti-obesity combination Contrave (bupropion SR/naltrexone SR).

This recommendation (although not binding for the FDA) was certainly met with a sigh of relief not just from investors but from many in the global obesity community. A final ruling from the FDA is due by January 31.

As both patients and health professionals are probably painfully aware, the recent withdrawal of sibutramine, has left us with almost no therapeutic options for obesity short of diet, exercise, orlistat or surgery.

Despite clearly voiced concerns about heart rate, blood pressure, seizures, anxiety and other potential safety issues with Contrave, the panel voted in favor of approving Contrave before the completion of a cardiovascular outcome trial.

A recommendation to perform a cardiovascular outcome trial prior to the launch of Contrave would have essentially killed this combination, or at least delayed its launch by five years or more.

While Contrave will clearly not be the magic bullet for obesity, I do think that this combination will find its place in the clinical arsenal of medical obesity treatments, thereby addressing a wide-open therapeutic gap.

As with sibutramine, there are likely to be strong contraindications and “black-box” warnings limiting its use in certain populations, but that was only to be expected. Both bupropion and naltrexone have well appreciated adverse effects and patients will have to be closely monitored both for efficacy and tolerability.

Nevertheless, I believe that this recommendation by the FDA panel will at least rekindle some enthusiasm in the search for new, safe and effective anti-obesity medications.

AMS
Ottawa, Canada

Disclaimer: I have received consulting honoraria from Orexigen the maker of Contrave

VN:F [1.9.22_1171]
Rating: 10.0/10 (1 vote cast)
VN:F [1.9.22_1171]
Rating: +1 (from 1 vote)
FDA Panel Not Contra Contrave, 10.0 out of 10 based on 1 rating

Leave a Comment

In The News

Diabetics in most need of bariatric surgery, university study finds

Oct. 18, 2013 – Ottawa Citizen: "Encouraging more men to consider bariatric surgery is also important, since it's the best treatment and can stop diabetic patients from needing insulin, said Dr. Arya Sharma, chair in obesity research and management at the University of Alberta." Read article

» More news articles...

Publications

  • Subscribe via Email

    Enter your email address:

    Delivered by FeedBurner




  • Arya Mitra Sharma
  • Disclaimer

    Postings on this blog represent the personal views of Dr. Arya M. Sharma. They are not representative of or endorsed by Alberta Health Services or the Weight Wise Program.
  • Archives

     

  • RSS Weighty Matters

  • Click for related posts

  • Disclaimer

    Medical information and privacy
    Any medical discussion on this page is intended to be of a general nature only. This page is not designed to give specific medical advice. If you have a medical problem you should consult your own physician for advice specific to your own situation.


  • Meta

  • Obesity Links

  • If you have benefitted from the information on this site, please take a minute to donate to its maintenance.

  • Home | News | KOL | Media | Publications | Trainees | About
    Copyright 2008–2014 Dr. Arya Sharma, All rights reserved.
    Blog Widget by LinkWithin